Inventia is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $8.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Inventia's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Inventia's share of it.